Welcome! Please Log In
Go
Omnicare's 3Q In Lineby Bill Buhr | 11-06-09 | 10:49AM | E-mail Article | Print Article
Browse Analyst Notes by Company : A B C D E F G H I J K L M N O P Q R S T U V W X Y Z All

Omnicare OCR reported adequate third-quarter earnings Thursday, and we are impressed by the company's overall performance through the first nine months of the year. With top-line growth fixed, Omnicare has made some strides to improve margins through cost initiatives. We are leaving our fair value estimate in place for now, but a strong finish to the year would make us consider increasing it.

Overall net revenue decreased around 2% to $1.54 billion from $1.58 billion in the year-ago quarter. The pharmacy services segment saw decreases in sales on lower reimbursements for certain drugs, along with the increased utilization of lower-cost generics. While this segment's adjusted operating profit fell around 6% year over year, overall operating income for the firm increased slightly on lower restructuring and litigation charges compared with the year-ago quarter. Overall cash generated through the first nine months of 2009 stood at $431 million.

In other news, the firm announced Tuesday it would pay $98 million to settle charges that it engaged in kickback schemes with nursing homes to send customers Omnicare's way. Omnicare denied wrongdoing and issued a statement indicating the settlement pre-empted a longer, more costly legal battle. This is not the first time Omnicare has paid significant penalties to settle allegations of wrongdoing, and this repeated pattern of behavior is what drives our very poor Stewardship Grade for the firm.


Get our full take on Omnicare, Inc.
See our complete company report and outlook--including fair value estimate, consider buying and selling prices, risk rating, bull and bear arguments, and star rating--with a free two-week Morningstar.com Premium Membership trial.

You will also get complete access to all 2,000 Stock Analyst Reports, 2,000 Mutual Fund Analyst Reports, and Morningstar's award-winning Portfolio Management and Screening tools.

Start my free trial
Learn more about Premium Membership
View Sample Analyst Report

More Analyst Research Omnicare, Inc. Full Analyst Report


Analyst Notes
08-11-09 | 11:49AM   Downgrading Omnicare's Moat

Sponsored Links
Bill Buhr is a stock analyst with Morningstar. Analyst Feedback.
Morningstar's editorial policies prohibit analysts from owning stocks they cover. Find out more about Morningstar's editorial policies here.
More Stock Analyst NotesAll Stock Analyst Notes
Morningstar's Latest ArticlesClick here to see the full list.
Sponsors Center
© Copyright 2009 Morningstar, Inc. All rights reserved. Please read our Terms of Use and Privacy Policy.
Omnicare's 3Q In Line bill.buhr@morningstar.com Omnicare's 3Q In Line OCR